Save this technology
close
Save to Existing Project
Save to a New Project
Esmolol 100mg/10ml Vial
Orpha Swiss GmbH Switzerland flag Switzerland
Abstract ID:
Ultrashort acting beta blocker Esmolol for use in anesthesia, intensive care, cardiology and internal medicine.
Contact
RE:
Participants
You

Esmolol is an ultra fast acting beta1-receptor blocker (cardio selective) with a very short elimination half-life of 9 minutes. This product is used for the short-term treatment of supraventricular tachycardia and for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short acting agent is desirable (e.g. myocardial infarct). Target groups are anaesthetists and ICU-clinicians. Generic version.

GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought

Country-specific or regional distribution contract.

FEATURED
Last Updated Sep 2013
Technology Type THERAPEUTIC
Phase of Development REGISTERED / FINISHED PRODUCT
CORPORATION
Company Logo

Opportunity Contact